CN110200985A - Application in NADH and/or NADPH Claritin and/or antiallergy health care product - Google Patents
Application in NADH and/or NADPH Claritin and/or antiallergy health care product Download PDFInfo
- Publication number
- CN110200985A CN110200985A CN201910503709.6A CN201910503709A CN110200985A CN 110200985 A CN110200985 A CN 110200985A CN 201910503709 A CN201910503709 A CN 201910503709A CN 110200985 A CN110200985 A CN 110200985A
- Authority
- CN
- China
- Prior art keywords
- claritin
- health care
- care product
- nadh
- antiallergy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The invention belongs to the applications in drug, health care product research and development field more particularly to NADH and/or NADPH Claritin and/or antiallergy health care product.The present invention provides a kind of application of the NADH and/or NADPH in Claritin and/or antiallergy health care product.In the present invention, NADH/NADPH is taken, Treg cell secretory immune is can induce and inhibits cell factor IL10, TGF-β etc., to inhibit the immune response of TH2, blood basophilla and tissue mast cell, it reduces sIgE synthesis while increasing sIgG and sIgA synthesis, to mitigate allergic symptom；Meanwhile the TH1 reaction of anaphylactogen specially can be also stimulated, cell factor IFN-γ and TGF-β are generated, the immune response of TH2, blood basophilla and tissue mast cell are inhibited, to reduce sIgE synthesis while increase sIgG and sIgA synthesis, to mitigate allergic symptom；Solve in the prior art, Claritin there are some adverse reactions, need medication repeatedly and allergy technological deficiency easy to recur, a kind of natural Claritin or health care product long-acting, with immunoregulation effect are provided.
Description
Technical field
The invention belongs to drug, health care product research and development field more particularly to NADH and/or NADPH Claritin and/or resist
Application in allergy health care product.
Background technique
Allergy is after common people partially are influenced with the little anaphylactogen factor in human body contact environment, and that is caused is a series of
The phenomenon that hypersensitivity phenomenon namely human body are for certain exogenous material excessive immunes.Allergy includes: i.e. hair property allergic reaction
(also known as IgE mediation type allergic reaction), antibody dependent type and cell poisoning allergic reaction, the allergic reaction of immunocomplex medium with
And delayed hypersensitivity reaction etc..
In the prior art, common antianaphylactic drug include: antihistamine, it is glucocorticoid, anti-leukotriene medicine, intranasal
Decongestant etc., there is certain adverse reaction in these drugs, and need control of medication symptom repeatedly, and allergy is easy recurrence.For gram
Above-mentioned adverse reaction is taken, has several latest report NADH treatment anaphylactic diseases, such as contact dermatitis, but be only limited to outer painting, and
Therapeutic effect is poor, easy to recur.
Therefore, the application in NADH and/or NADPH Claritin and/or antiallergy health care product is developed, for solving
In the prior art, Claritin there are some adverse reactions, need medication repeatedly and allergy technological deficiency easy to recur, become
Those skilled in the art's urgent problem to be solved.
Summary of the invention
In view of this, the present invention provides answering in NADH and/or NADPH Claritin and/or antiallergy health care product
With, for solving in the prior art, Claritin there are some adverse reactions, need medication repeatedly and allergy technology easy to recur
Defect.
The present invention provides a kind of icotinamide-adenine dinucleo (NADH) and/or nicotinamide-adenine-phosphoric acid-two
Application of the nucleotide (NADPH) in Claritin and/or antiallergy health care product.
Preferably, a kind of icotinamide-adenine dinucleo (NADH) and nicotinamide-adenine-phosphoric acid-dinucleotides
(NADPH) application of the composition in Claritin and/or antiallergy health care product.
Preferably, the allergic reaction of the Claritin and/or antiallergy health care product is selected from: allergic asthma, allergy
Any one or more in property rhinitis, allergic conjunctivitis, drug allergy, food hypersenstivity, pollen hypersensitivity and oral cavity allergy.
Preferably, in the composition, icotinamide-adenine dinucleo (NADH) and nicotinamide-adenine-phosphoric acid-
The mass ratio of dinucleotides (NADPH) is (1~10): (1~10).
Preferably, the icotinamide-adenine dinucleo (NADH) is reproducibility icotinamide-adenine dinucleo
(NADH)。
Preferably, the allergic reaction of the Claritin and/or antiallergy health care product is selected from: IL10, TGF-β and
Protein expression composed by IFN-γ immuno-suppressing cytokine.
Preferably, the dosage form of the Claritin and/or antiallergy health care product is oral agents or injection.
Preferably, the oral agents are selected from: tablet, pulvis, capsule, granule, pill, suspension, syrup, conjunction
Any one or more in agent, powder and dripping pill.
Preferably, the auxiliary material of the Claritin and/or antiallergy health care product is selected from: mannitol, microcrystalline cellulose, hard
Any one or more in fatty acid magnesium, carboxymethyl cellulose and calcium monohydrogen phosphate；
Lactose is not contained in the drug and/or health care product.
Preferably, the icotinamide-adenine dinucleo or nicotinamide-adenine-oral list of phosphoric acid-dinucleotides
Secondary dosage is 0.1~10mg/kg, and taking orally number day is 1~3 time；
The icotinamide-adenine dinucleo or nicotinamide-adenine-phosphoric acid-dinucleotides injection single dose
For 0.1~2mg/kg.
Preferably, in the Claritin and/or antiallergy health care product, except icotinamide-adenine dinucleo and/or
Other antiallergic activity ingredients are not contained outside nicotinamide-adenine-phosphoric acid-dinucleotides.
In practical application, can be according to anaphylactoid severity, administration mode and the specific physiology phase of autopath
The dosage of NADH and/or NADPH is adjusted flexibly in pass factor；Wherein, the safe dose of single oral NADH and/or NADPH is
0.1~10mg/kg, preferably 0.1~4mg/kg, take orally day suitable NADH and/or NADPH safe dose be 0.1~
30mg/kg, preferably 0.1~12mg/kg, more preferable 0.4~2mg/kg；When for conventional note can be prepared into when injecting
Agent is penetrated, the single safe dose of injection NADH and/or NADPH is 0.1~2mg/kg, preferably 0.1~1mg/kg.
In the present invention, NADH and/or NADPH are applied as active constituent in preparation treatment Claritin or health care product
In, a kind of natural Claritin or health care product long-acting, with immunoregulation effect are provided；Further, the present invention provides
Technical solution in, used oral preparation, treatment is delayed type hypersensitivity, and what is utilized is that NADH is able to ascend immunity,
To have the function that long-acting, improvement allergic constitution to treat allergy.
In conclusion the present invention provides a kind of icotinamide-adenine dinucleo (NADH) and/or niacinamide-gland are fast
Purine-application of the phosphoric acid-dinucleotides (NADPH) in Claritin and/or antiallergy health care product.Technology provided by the invention
In scheme, NADH/NADPH is taken, Treg cell secretory immune is can induce and inhibits cell factor IL10, TGF-β etc., to inhibit
The immune response of TH2, blood basophilla and tissue mast cell reduce sIgE synthesis while increasing sIgG and sIgA synthesis, from
And mitigate allergic symptom；Meanwhile the TH1 reaction of anaphylactogen specially can be also stimulated, generate cell factor IFN-γ and TGF-β, suppression
The immune response of TH2, blood basophilla and tissue mast cell processed are closed to reduce sIgE synthesis while increase sIgG and sIgA
At to mitigate allergic symptom.In NADH and/or NADPH Claritin and/or antiallergy health care product provided by the invention
Using, solve in the prior art, Claritin there are some adverse reactions, need medication repeatedly and allergy technology easy to recur
Defect provides a kind of natural Claritin or health care product long-acting, with immunoregulation effect.
Specific embodiment
The embodiment of the invention provides the application in NADH and/or NADPH Claritin and/or antiallergy health care product,
For solving in the prior art, Claritin there are some adverse reactions, need medication repeatedly and allergy technology easy to recur to lack
It falls into, a kind of natural Claritin or health care product long-acting, with immunoregulation effect is provided.
The technical scheme in the embodiments of the invention will be clearly and completely described below, it is clear that described implementation
Example is only a part of the embodiment of the present invention, instead of all the embodiments.Based on the embodiments of the present invention, this field is common
Technical staff's every other embodiment obtained without making creative work belongs to the model that the present invention protects
It encloses.
In order to which the present invention is described in more detail, below with reference to embodiment to NADH and/or NADPH antiallergy provided by the invention
Application in drug and/or antiallergy health care product, is specifically described.
The present invention provides a kind of icotinamide-adenine dinucleo (NADH) and/or nicotinamide-adenine-phosphoric acid-two
Application of the nucleotide (NADPH) in Claritin and/or antiallergy health care product.
In technical solution provided by the invention, NADH/NADPH is taken, Treg cell secretory immune is can induce and inhibits cell
Factor IL10, TGF-β etc. reduce sIgE synthesis to inhibit the immune response of TH2, blood basophilla and tissue mast cell
Increase sIgG and sIgA synthesis simultaneously, it is final to mitigate allergic symptom alternatively, taking NADH/NADPH, also it can stimulate anaphylactogen specially
TH1 reaction, generate cell factor IFN-γ and TGF-β, inhibit the immune anti-of TH2, blood basophilla and tissue mast cell
It answers, to reduce sIgE synthesis while increase sIgG and sIgA synthesis, finally mitigates allergic symptom.
Meanwhile further combined with Examples 1 to 6 it can be concluded that, NADH and/or NADPH have allergic reaction good
Inhibition and therapeutic effect.
It can be obtained according to experiment statistics, in technical solution provided by the invention, the antiallergy as made from NADH and/or NADPH
The allergic reaction of drug and/or antiallergy health care product is selected from: allergic asthma, allergic rhinitis, allergic conjunctivitis, drug mistake
Any one or more in quick, food hypersenstivity, pollen hypersensitivity and oral cavity allergy.
Further, according to NADH and/or NADPH action target spot, in technical solution provided in an embodiment of the present invention, anti-mistake
The allergic reaction of sensitizing drug and/or antiallergy health care product is selected from: IL10, TGF-β and IFN-γ immuno-suppressing cytokine institute
The protein expression of composition.
During practical application, the Claritin as made from NADH and/or NADPH and/or antiallergy health care product
Dosage form be selected from: tablet, injection, pulvis, capsule, granule, pill, suspension, syrup, mixture, powder and drop
Any one or more in ball.
It is the NADH that effectively prevent and/or NADPH gastric acid is unstable, easy decomposition, its bioavilability reduces after decomposition,
To effectively improve in bioavilability technical solution provided in an embodiment of the present invention, the coating of coated tablet is acid stable packet
Clothing.
To allow NADH and/or NADPH product to maintain preferable form, convenient for taking and improve product storage life
The design requirement of limit, in technical solution provided in an embodiment of the present invention, the auxiliary material of Claritin and/or antiallergy health care product is selected
From: any one or more in mannitol, microcrystalline cellulose, magnesium stearate, carboxymethyl cellulose and calcium monohydrogen phosphate.
In technical solution provided by the invention, in obtained drug and/or health care product, without containing lactose as auxiliary material,
Drug effect is reduced to prevent lactose and NADH and/or NADPH from reacting.
According to clinical trial measurement result, take into account with good antiallergic effect and lower adverse reaction, the present invention is real
In the technical solution that example offer is provided ,-two core of icotinamide-adenine dinucleo (NADH) and/or nicotinamide-adenine-phosphoric acid
The oral single dose of thuja acid (NADPH) is 0.1~10mg/kg；Icotinamide-adenine dinucleo (NADH) and/or nicotinoyl
The suitable bolus doses of amine-adenine-phosphoric acid-dinucleotides (NADPH) are 0.1~2mg/kg.
Embodiment 1
In the present embodiment, C3H/HeJ peanut allergy mouse is prepared with following methods: 6 week old female C3H/HeJ are small
Mouse is purchased from Shanghai Experimental Animal Center.Animal subject is 21 DEG C~23 in mean temperature under the conditions of specific no pathogenicity
DEG C, in the room of relative humidity 40%~70%, illumination/dark cycle raising in 12 hours.
The daily stomach-filling peanut homogenate (single 80mg/ every) of sensitization group mouse the 21st day after sensitization measure implementation, is given
Injection (i.p) injection 30mg CPE (peanut extract)/mouse in mouse peritoneal is given, is used as yin from not in contact with the young rat for crossing peanut
Property control.Then, it (by measurement vascular leakage, monitoring clinical symptoms, rectal temperature, is exhaled by skin experiment and allergic reaction
Inhale frequency and measure serum in mast cell protease 1-1 (mmcp-1)-mast cell degranulation specific marker object) inspection
It surveys and determines being successfully established for sensitized mice model.
1.1 animal and experiment reagent:
6 week old C3H/HeJ female mices (strain: C3H/HeJ, Shanghai Experimental Animal Center purchase), IL10, TGF-β,
IFN-γ and IgE antibody (Sigma-aldrich purchase), NADH (is provided for oneself).
1.2 experimental method
It takes 6 wild-type mices and 24 peanut sensitized mices at random and peanut sensitized mice is randomly divided into 4 groups, every group
6 mouse.It is grouped as follows:
1., blank group: C3H/HeJ wild-type mice (injecting normal saline 10mg/kg weight)；
2., processing group 1:C3H/HeJ peanut allergy mouse (injection NADH 1mg/kg weight)；
3., processing group 2:C3H/HeJ peanut allergy mouse (injection NADH 5mg/kg weight)；
4., processing group 3:C3H/HeJ peanut allergy mouse (injection NADH 10mg/kg weight)；
5., control group 4:C3H/HeJ peanut allergy mouse (injecting normal saline 10mg/kg weight)
30mg CPE is injected intraperitoneally in C3H/HeJ wild-type mice and C3H/HeJ peanut allergy mouse, and (peanut extracts
Object) after/mouse sensitization.Blank control group injecting normal saline 10mg/kg weight, processing group 1~3 inject NADH 1mg/ respectively
Kg weight, 5mg/kg weight, 10mg/kg weight, 4 injecting normal saline 10mg/kg weight of processing group.
16 hours after medication, each group mouse inner canthus venous blood is taken, detects cellular immunity in mouse peripheral blood serum
Inhibiting factor IL10, TGF-β, the content of IFN-γ and IgE.
1.3 result
Various concentration NADH processing C3H/HeJ peanut allergy mouse can be different degrees of increase peripheral blood in cell
Immunosuppressive factor IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE.
The elisa plate for being coated with 5 μ g/mL recombinant proteins is stayed overnight, and is then closed with 2%BSA (98% PBS).By serum sample
Product are diluted in 1%BSA with 1:500 times, then carry out 1:3 serial dilution.In order to detect IgE, with agarose-Protein G
(Thermo Fisher Scientific, Rockford, IL) is handled serum 50 minutes, then by the diluted sample loading of 1:20
Onto elisa plate.With corresponding antibody test sample.
With SureBlue tmb substrate (KPL, Gaithersburg, MD) react, and with TMB stop bath (KPL,
Gaithersburg, MD) terminate reaction.Result is read with Epoch ELISA reader (BioTek, Winooski, VT).With it is right
According to the C3H/HeJ peanut allergy mouse for the NADH processing for organizing different concentration can be different degrees of increase peripheral blood in cell
Immunosuppressive factor IL10, TGF-β, the content of IFN-γ simultaneously reduce the content results of allergic protein IgE and are shown in Table 1.
Table 1 is that injection NADH increases anaphylaxis mouse model Cellular immunity suppression factor IL10, TGF-β and IFN-γ level
And reduce IgE antibody horizontal values table.
Table 1
| Grouping | IFN-γ | TGF-β | IL-10 | IgE |
| Blank group | 426±3.54pg/ml | 41.26±4.08pg/ml | 9.63±0.77pg/ml | 2.32±0.29KU/L |
| Control group | 219±6.63pg/ml | 29.85±5.23pg/ml | 5.79±2.06pg/ml | 4.27±0.31KU/L |
| Processing group 1 | 388±5.02pg/ml | 36.63±3.95pg/ml | 8.02±1.18pg/ml | 3.38±0.24KU/L |
| Processing group 2 | 437±2.05pg/ml | 43.09±4.28pg/ml | 9.07±2.25pg/ml | 2.22±0.19KU/L |
| Processing group 3 | 418±5.53pg/ml | 39.46±5.66pg/ml | 9.81±1.39pg/ml | 2.52±0.48KU/L |
Embodiment 2
C3H/HeJ peanut allergy mouse is prepared with following methods in test example of the present invention: 6 week old female C3H/HeJ
Mouse is purchased from Shanghai Experimental Animal Center.Animal subject is 21 DEG C -23 in mean temperature under the conditions of specific no pathogenicity
DEG C, in the room of relative humidity 40%-70%, illumination/dark cycle raising in 12 hours.
The daily stomach-filling peanut homogenate (single 80mg/ every) of sensitization group mouse the 21st day after sensitization measure implementation, is given
Injection (i.p) injection 30mg CPE (peanut extract)/mouse in mouse peritoneal is given, is used as yin from not in contact with the young rat for crossing peanut
Property control.Then measurement vascular leakage, monitoring clinical symptoms, rectal temperature, breathing (are passed through by skin experiment and allergic reaction
Frequency and measurement serum in mast cell protease 1-1 (mmcp-1)-mast cell degranulation specific marker object) detection
Determine being successfully established for sensitized mice model.
2.1 animals and experiment reagent:
6 week old C3H/HeJ female mices (strain: C3H/HeJ, Shanghai Experimental Animal Center purchase), IL10, TGF-β,
IFN-γ and IgE antibody (Sigma-aldrich purchase), NADH (is provided for oneself).
2.2 experimental method
6 wild-type mices and 24 peanut sensitized mices are taken at random, and peanut sensitized mice is randomly divided into 4 groups, often
6 mouse of group.It is grouped as follows:
1., blank group: C3H/HeJ wild-type mice (gives general diet)；
2., processing group 1:C3H/HeJ peanut allergy mouse (general diet and oral supplementation NADH are given in sensitization process
1mg/kg weight (contains auxiliary material)；
3., processing group 2:C3H/HeJ peanut allergy mouse (general diet and oral supplementation NADH are given in sensitization process
10mg/kg weight (contains auxiliary material)；
4., processing group 3:C3H/HeJ peanut allergy mouse (general diet and oral supplementation NADH are given in sensitization process
20mg/kg weight (contains auxiliary material)；
5., control group: C3H/HeJ peanut allergy mouse (given in sensitization process general diet and with 3 equivalent of processing group
Auxiliary material)
C3H/HeJ wild-type mice (giving general diet) and C3H/HeJ mouse are supplemented not in peanut sensitization process
With concentration NADH, after each group mouse is raised 21 days.Each group mouse is injected intraperitoneally 30mg CPE (peanut extract)/mouse and causes
It is quick.
After injecting CPE sensitization, each group mouse inner canthus venous blood is taken, detects Cellular immunity suppression in mouse peripheral blood serum
Factor IL10, TGF-β, the content of IFN-γ and IgE.
3.3 result
Various concentration NADH processing C3H/HeJ peanut allergy mouse can be different degrees of increase peripheral blood in cell
Immunosuppressive factor IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE.It is coated with 5 μ g/mL recombinant proteins
Elisa plate stay overnight, then with 2%BSA (98% PBS) close.Blood serum sample is diluted in 1%BSA with 1:500 times,
Then 1:3 serial dilution is carried out.In order to detect IgE, with agarose-Protein G (Thermo Fisher Scientific,
Rockford, IL) processing serum 50 minutes, then the diluted sample of 1:20 is loaded on elisa plate.
With corresponding antibody test sample.It is reacted, is used in combination with SureBlue tmb substrate (KPL, Gaithersburg, MD)
TMB stop bath (KPL, Gaithersburg, MD) terminates reaction.With Epoch ELISA reader (BioTek, Winooski,
VT result) is read.What the C3H/HeJ peanut allergy mouse of the NADH processing of various concentration can be different degrees of compared with the control group
Increase Cellular immunity suppression factor IL10, TGF-β, the content of IFN-γ and the content knot for reducing allergic protein IgE in peripheral blood
Fruit is shown in Table 2.
Table 2 is that oral NADH increases anaphylaxis mouse model Cellular immunity suppression factor IL10, TGF-β and IFN-γ level
And reduce IgE antibody horizontal values table.
Table 2
Embodiment 3
3.1 experimental materials and experiment reagent:
Healthy children peripheral blood and children with food allergy peripheral blood (PBMC) of the same age comes from Shenzhen Children's Hospital.
IL10, TGF-β, IFN-γ and IgE antibody (Sigma-aldrich purchase), NADH (is provided for oneself).3.2 experimental method
PBMC has been suspended in 10% certainly by the peripheral blood and children with food allergy peripheral blood (PBMC) for taking healthy children at random
Culture medium (the RPMI-1640 of body blood plasma；Mediatech in), and at 37 DEG C, 5%CO2Culture is grouped such as in cell incubator
Under:
1., healthy group: healthy youngster PBMC (10^7/ml) is suspended in culture in culture medium and (physiological saline is added in culture medium
0.2mg/ml；
2., blank group: related allergy children PBMC (10^7/ml) is suspended in culture medium culture and (is added in culture medium
Physiological saline 0.2mg/ml)；
3., processing group 1: related allergy children PBMC (10^7/ml) be suspended in culture medium culture (in culture medium plus
NADH 0.02mg/ml)；
4., processing group 2: related allergy children PBMC (10^7/ml) is suspended in culture medium culture and (is added in culture medium
NADH 0.1mg/ml)；
5., processing group 3: related allergy children PBMC (10^7/ml) is suspended in culture medium culture and (is added in culture medium
NADH 0.2mg/ml)
Various concentration NADH in vitro culture is added in the culture medium of each group PBMC and detects 5 groups by ELISA after 72 hours
IgE in serum in peripheral blood, IL-10, the content of IFN-γ and TGF-β.
3.3 result
Various concentration NADH processing PBMC can be different degrees of increase peripheral blood in the Cellular immunity suppression factor
IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE；
The elisa plate for being coated with 5 μ g/mL recombinant proteins is stayed overnight, and is then closed with 2%BSA (98% PBS).By culture medium
Supernatant is diluted in 1%BSA with 1:500 times, then carries out 1:3 serial dilution.In order to detect IgE, with agarose-Protein G
(Thermo Fisher Scientific, Rockford, IL) is handled serum 50 minutes, then by the diluted sample loading of 1:20
Onto elisa plate.With corresponding antibody test sample.It is reacted with SureBlue tmb substrate (KPL, Gaithersburg, MD),
And it is terminated and is reacted with TMB stop bath (KPL, Gaithersburg, MD).With Epoch ELISA reader (BioTek,
Winooski, VT) read result.The PBMC of the children with food allergy of the NADH processing of various concentration compared with the control group, can
Cellular immunity suppression factor IL10, TGF-β, the content of IFN-γ and allergic protein is reduced in different degrees of increase peripheral blood
The content results of IgE are shown in Table 3.
Table 3 is that addition NADH cultivates children with food allergy peripheral blood (PBMC) in the medium, increases children with food allergy
PBMC Cellular immunity suppression factor IL10, TGF-β and IFN-γ are horizontal and reduce IgE antibody horizontal values table.
Table 3
| Grouping | IFN-γ | TGF-β | IL-10 | IgE |
| Healthy group | 108.53±11.1pg/L | 89.53±5.6pg/ml | 47.11±4.7pg/ml | 351±6.3U/ml |
| Blank group | 69.09±9.57pg/L | 51.46±6.3pg/ml | 38.04±3.26pg/ml | 589±10.2U/ml |
| Processing group 1 | 99.23±6.28pg/L | 70.29±4.2pg/ml | 49.37±2.6pg/ml | 452±9.7U/ml |
| Processing group 2 | 115.22±7.74pg/L | 91.81±3.48pg/ml | 46.54±4.10pg/ml | 370±5.96U/ml |
| Processing group 3 | 130.06±5.67pg/L | 87.24±5.1pg/ml | 50.88±5.1pg/ml | 382±8.43U/ml |
Embodiment 4
C3H/HeJ peanut allergy mouse is prepared with following methods in test example of the present invention: 6 week old female C3H/HeJ
Mouse is purchased from Shanghai Experimental Animal Center.Animal subject is 21 DEG C -23 in mean temperature under the conditions of specific no pathogenicity
DEG C, in the room of relative humidity 40%-70%, illumination/dark cycle raising in 12 hours.
The daily stomach-filling peanut homogenate (single 80mg/ every) of sensitization group mouse the 21st day after sensitization measure implementation, is given
Injection (i.p) injection 30mg CPE (peanut extract)/mouse in mouse peritoneal is given, is used as yin from not in contact with the young rat for crossing peanut
Property control.Then measurement vascular leakage, monitoring clinical symptoms, rectal temperature, breathing (are passed through by skin experiment and allergic reaction
Frequency and measurement serum in mast cell protease 1-1 (mmcp-1)-mast cell degranulation specific marker object) detection
Determine being successfully established for sensitized mice model.
4.1 animals and experiment reagent:
6 week old C3H/HeJ female mices (strain: C3H/HeJ, Shanghai Experimental Animal Center purchase), IL10, TGF-β,
IFN-γ and IgE antibody (Sigma-aldrich purchase), NADPH (is provided for oneself).
4.2 experimental method
6 wild-type mices and 24 peanut sensitized mices are taken at random, and peanut sensitized mice is randomly divided into 4 groups, often
6 mouse of group.It is grouped as follows:
1., blank group: C3H/HeJ wild-type mice (injecting normal saline 10mg/kg weight)；
2., processing group 1:C3H/HeJ peanut allergy mouse (injection NADPH 1mg/kg weight)；
3., processing group 2:C3H/HeJ peanut allergy mouse (injection NADPH 5mg/kg weight)；
4., processing group 3:C3H/HeJ peanut allergy mouse (injection NADPH 10mg/kg weight)；
5., control group 4:C3H/HeJ peanut allergy mouse (injecting normal saline 10mg/kg weight)
30mg CPE is injected intraperitoneally in C3H/HeJ wild-type mice and C3H/HeJ peanut allergy mouse, and (peanut extracts
Object) after/mouse sensitization.Blank control group injecting normal saline 10mg/kg weight, processing group 1-3 inject injection NADPH respectively
1mg/kg weight, 5mg/kg weight, 10mg/kg weight, 4 injecting normal saline 10mg/kg weight of processing group.
16 hours after medication, each group mouse inner canthus venous blood is taken, detects cellular immunity in mouse peripheral blood serum
Inhibiting factor IL10, TGF-β, the content of IFN-γ and IgE.
4.3 result
It is thin in the increase peripheral blood that the C3H/HeJ peanut allergy mouse of the NADPH processing of various concentration can be different degrees of
Born of the same parents' immunosuppressive factor IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE.
The elisa plate for being coated with 5 μ g/mL recombinant proteins is stayed overnight, and is then closed with 2%BSA (98% PBS).By serum sample
Product are diluted in 1%BSA with 1:500 times, then carry out 1:3 serial dilution.In order to detect IgE, with agarose-Protein G
(Thermo Fisher Scientific, Rockford, IL) is handled serum 50 minutes, then by the diluted sample loading of 1:20
Onto elisa plate.
With corresponding antibody test sample.It is reacted, is used in combination with SureBlue tmb substrate (KPL, Gaithersburg, MD)
TMB stop bath (KPL, Gaithersburg, MD) terminates reaction.With Epoch ELISA reader (BioTek, Winooski,
VT result) is read.The C3H/HeJ peanut allergy mouse of the NADPH processing of various concentration can be different degrees of compared with the control group
Increase peripheral blood in Cellular immunity suppression factor IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE
It the results are shown in Table 4.
Table 4 is that injection NADPH increases anaphylaxis mouse model Cellular immunity suppression factor IL10, TGF-β and IFN-γ water
Flat and reduction IgE antibody horizontal values table
Table 4
Embodiment 5
C3H/HeJ peanut allergy mouse is prepared with following methods in test example of the present invention: 6 week old female C3H/HeJ
Mouse is purchased from Shanghai Experimental Animal Center.Animal subject is 21 DEG C~23 in mean temperature under the conditions of specific no pathogenicity
DEG C, in the room of relative humidity 40%~70%, illumination/dark cycle raising in 12 hours.The daily stomach-filling of sensitization group mouse
Peanut is homogenized (single 80mg/ every).
The 21st day after sensitization measure implementation, giving injection (i.p) injection 30mg CPE in mouse peritoneal, (peanut extracted
Object)/mouse, from the young rat not in contact with peanut excessively as negative control.Then measurement (is passed through by skin experiment and allergic reaction
Mast cell protease 1-1 (mmcp-1)-in vascular leakage, monitoring clinical symptoms, rectal temperature, respiratory rate and measurement serum
The specific marker object of mast cell degranulation) detection determine that sensitized mice model is successfully established.
5.1 animals and experiment reagent
6 week old C3H/HeJ female mices (strain: C3H/HeJ, Shanghai Experimental Animal Center purchase), IL10, TGF-β,
IFN-γ and IgE antibody (Sigma-aldrich purchase), NADPH (is provided for oneself).
5.2 experimental method
6 wild-type mices and 24 peanut sensitized mices are taken at random, and peanut sensitized mice is randomly divided into 4 groups, often
6 mouse of group.It is grouped as follows:
1., blank group: C3H/HeJ wild-type mice (gives general diet)；
2., processing group 1:C3H/HeJ peanut allergy mouse (general diet and oral supplementation are given in sensitization process
NADPH1mg/kg weight (contains auxiliary material)；
3., processing group 2:C3H/HeJ peanut allergy mouse (general diet and oral supplementation are given in sensitization process
NADPH10mg/kg weight (contains auxiliary material)；
4., processing group 3:C3H/HeJ peanut allergy mouse (general diet and oral supplementation are given in sensitization process
NADPH 20mg/kg weight (contains auxiliary material)；
5., control group: C3H/HeJ peanut allergy mouse (given in sensitization process general diet and with 3 equivalent of processing group
Auxiliary material)
C3H/HeJ wild-type mice (giving general diet) and C3H/HeJ mouse are supplemented not in peanut sensitization process
After the raising of each group mouse 21 days of concentration NADPH.Each group mouse is injected intraperitoneally 30mgCPE (peanut extract)/mouse and causes
It is quick.
After injecting CPE sensitization, each group mouse inner canthus venous blood is taken, detects Cellular immunity suppression in mouse peripheral blood serum
Factor IL10, TGF-β, the content of IFN-γ and IgE.
5.3 result
It is thin in the increase peripheral blood that the C3H/HeJ peanut allergy mouse of the NADPH processing of various concentration can be different degrees of
Born of the same parents' immunosuppressive factor IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE.
The elisa plate for being coated with 5 μ g/mL recombinant proteins is stayed overnight, and is then closed with 2%BSA (98% PBS).By serum sample
Product are diluted in 1%BSA with 1:500 times, then carry out 1:3 serial dilution.In order to detect IgE, with agarose-Protein G
(Thermo Fisher Scientific, Rockford, IL) is handled serum 50 minutes, then by the diluted sample loading of 1:20
Onto elisa plate.
With corresponding antibody test sample.It is reacted, is used in combination with SureBlue tmb substrate (KPL, Gaithersburg, MD)
TMB stop bath (KPL, Gaithersburg, MD) terminates reaction.With Epoch ELISA reader (BioTek, Winooski,
VT result) is read.The C3H/HeJ peanut allergy mouse of the NADPH processing of various concentration can be different degrees of compared with the control group
Increase peripheral blood in Cellular immunity suppression factor IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE
It the results are shown in Table 5.
Table 5 is that oral NADPH increases anaphylaxis mouse model Cellular immunity suppression factor IL10, TGF-β and IFN-γ water
Flat and reduction IgE antibody horizontal values table
Table 5
| Grouping | IFN-γ | TGF-β | IL-10 | IgE |
| Blank group | 433±3.2pg/ml | 40.9±2.8pg/ml | 10.01±0.52pg/ml | 2.68±0.68KU/L |
| Control group | 254±5.11pg/ml | 20.12±5.35pg/ml | 7.29±0.93pg/ml | 6.92±0.44KU/L |
| Processing group 1 | 246±7.64pg/ml | 25.36±3.15pg/ml | 7.96±1.01pg/ml | 5.06±0.49KU/L |
| Processing group 2 | 389±2.65pg/ml | 43.21±4.12pg/ml | 12.50±0.87pg/ml | 2.94±0.81KU/L |
| Processing group 3 | 426±3.43pg/ml | 40.67±8.01pg/ml | 11.00±1.26pg/ml | 3.21±0.24KU/L |
Embodiment 6
6.1 experimental materials and experiment reagent:
Healthy children peripheral blood and children with food allergy peripheral blood (PBMC) of the same age comes from Shenzhen Children's Hospital.
IL10, TGF-β, IFN-γ and IgE antibody (Sigma-aldrich purchase).
6.2 experimental method
PBMC has been suspended in 10% certainly by the peripheral blood and children with food allergy peripheral blood (PBMC) for taking healthy children at random
Culture medium (the RPMI-1640 of body blood plasma；Mediatech in), and culture is grouped such as in 37 DEG C, 5%CO2 cell incubator
Under:
1., healthy group: healthy youngster PBMC (10^7/ml) is suspended in culture in culture medium and (physiological saline is added in culture medium
0.2mg/ml)；
2., blank group: related allergy children PBMC (10^7/ml) is suspended in culture medium culture and (is added in culture medium
Physiological saline 0.2mg/ml)；
3., processing group 1: related allergy children PBMC (10^7/ml) be suspended in culture medium culture (in culture medium plus
NADPH 0.02mg/ml)；
4., processing group 2: related allergy children PBMC (10^7/ml) is suspended in culture medium culture and (is added in culture medium
NADPH 0.1mg/ml)；
5., processing group 3: related allergy children PBMC (10^7/ml) is suspended in culture medium culture and (is added in culture medium
NADPH 0.2mg/ml)
Various concentration NADPH in vitro culture is added in the culture medium of each group PBMC and detects 4 groups by ELISA after 72 hours
IgE in serum in peripheral blood, IL-10, the content of IFN-γ and TGF-β.
6.3 result
Various concentration NADPH processing PBMC can be different degrees of increase peripheral blood in the Cellular immunity suppression factor
IL10, TGF-β, the content of IFN-γ and the content for reducing allergic protein IgE.
The elisa plate for being coated with 5 μ g/mL recombinant proteins is stayed overnight, and is then closed with 2%BSA (98% PBS).By culture medium
Supernatant is diluted in 1%BSA with 1:500 times, then carries out 1:3 serial dilution.In order to detect IgE, with agarose-Protein G
(Thermo Fisher Scientific, Rockford, IL) is handled serum 50 minutes, then by the diluted sample loading of 1:20
Onto elisa plate.With corresponding antibody test sample.It is reacted with SureBlue tmb substrate (KPL, Gaithersburg, MD),
And it is terminated and is reacted with TMB stop bath (KPL, Gaithersburg, MD).With Epoch ELISA reader (BioTek,
Winooski, VT) read result.The PBMC of the children with food allergy of the NADPH processing of various concentration compared with the control group, can
Cellular immunity suppression factor IL10, TGF-β, the content of IFN-γ and allergic protein is reduced in different degrees of increase peripheral blood
The content results of IgE are shown in Table 6.
Table 6 is that addition NADPH cultivates children with food allergy peripheral blood (PBMC) in the medium, increases children with food allergy
PBMC=Cellular immunity suppression factor IL10, TGF-β and IFN-γ are horizontal and reduce IgE antibody horizontal values table.
Table 6
Embodiment 7
60 allergic asthmas and 60 Allergic Rhinitis, wherein male 40, female 40,12 years old or less children 40
Example.Pathogenic factor is diagnosed as delayed type hypersensitivity caused by chemical contact, respiratory tract sucking etc., has excluded organic disease, outer
The non-allergic cases such as wound.Stochastic averagina is divided into 4 groups, respectively 1 group control group, experiment (NADH 10mg), tests 2 groups
(NADPH 10mg) tests 3 groups (NADH:NADPH 5:5mg), and each group gender, age, course of disease etc. are statistically analyzed, difference
Without significant, it is comparable.
Control group gives loratadine tablet (10mg/ piece), uses, continuously takes one month by package insert.
It tests 1 group and gives NADH 10mg, daily morning is primary on an empty stomach, continuously takes 1 month.
It tests 2 groups and gives NADPH 10mg, daily morning is primary on an empty stomach, continuously takes 1 month.
It tests 3 groups and gives NADH:NADPH 5mg:5mg, daily morning is primary on an empty stomach, continuously takes 1 month.
Diagnostic criteria
Invalid: patient symptom absolutely not improves, and has exacerbation sign；
Effective: patient symptom is significantly improved, but does not completely disappear yet；
Effective: patient symptom completely disappears.
Side reaction: drowsiness, dizzy, absent minded etc..
Treatment results:
The total effective rate (%) of each group treatment is investigated, and 1 month, 3 months, 6 months recurrence rates (%) after being discontinued, knot
Fruit is shown in Table 7.
Table 7
From upper 7 result of table it is found that compared with the control group, the present invention tests 1 group, 2 groups and 3 groups, for allergic rhinitis,
The therapeutic effect of allergic asthma and the therapeutic effect of Loratadine are suitable, it was demonstrated that NADH, NADPH and combinations thereof can be controlled effectively
Treat Delayed Hypersensitivity disease.In terms of recurrence rate, the recurrence rate after 6 months is below 23%, well below control group
87.5%, it was demonstrated that NADH and/or NADPH can significantly reduce the recurrence rate of anaphylactia.
Over the course for the treatment of, control group occurs side reaction 18, and each experimental group occurs without side reaction.
In conclusion the present invention provides a kind of icotinamide-adenine dinucleo (NADH) and/or niacinamide-gland are fast
Purine-application of the phosphoric acid-dinucleotides (NADPH) in Claritin and/or antiallergy health care product.Technology provided by the invention
In scheme, NADH/NADPH is taken, Treg cell secretory immune is can induce and inhibits cell factor IL10, TGF-β etc., to inhibit
The immune response of TH2, blood basophilla and tissue mast cell reduce sIgE synthesis while increasing sIgG and sIgA synthesis, from
And mitigate allergic symptom；Meanwhile the TH1 reaction of anaphylactogen specially can be also stimulated, generate cell factor IFN-γ and TGF-β, suppression
The immune response of TH2, blood basophilla and tissue mast cell processed are closed to reduce sIgE synthesis while increase sIgG and sIgA
At to mitigate allergic symptom.In NADH and/or NADPH Claritin and/or antiallergy health care product provided by the invention
Using, solve in the prior art, Claritin there are some adverse reactions, need medication repeatedly and allergy technology easy to recur
Defect provides a kind of natural Claritin or health care product long-acting, with immunoregulation effect.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (10)
1. a kind of icotinamide-adenine dinucleo and/or nicotinamide-adenine-phosphoric acid-dinucleotides are in Claritin
And/or the application in antiallergy health care product.
2. application according to claim 1, which is characterized in that a kind of icotinamide-adenine dinucleo and niacinamide-gland
Application of the purine-phosphoric acid-dinucleotides composition in Claritin and/or antiallergy health care product.
3. application according to claim 1, which is characterized in that the mistake of the Claritin and/or antiallergy health care product
Quick reaction is selected from: allergic asthma, allergic rhinitis, allergic conjunctivitis, drug allergy, food hypersenstivity, pollen hypersensitivity and mouth
Any one or more in chamber allergy.
4. application according to claim 2, which is characterized in that in the composition, icotinamide-adenine dinucleo and
Nicotinamide-adenine-phosphoric acid-dinucleotides mass ratio is (1~10): (1~10).
5. application according to claim 1 or 2, which is characterized in that the icotinamide-adenine dinucleo is reproducibility
Icotinamide-adenine dinucleo.
6. application according to claim 1 or 2, which is characterized in that the Claritin and/or antiallergy health care product
Allergic reaction is selected from: protein expression composed by IL10, TGF-β and IFN-γ immuno-suppressing cytokine.
7. application according to any one of claims 1 or 2, which is characterized in that the Claritin and/or antiallergy
The dosage form of health care product is oral agents or injection.
8. application according to claim 7, which is characterized in that the oral agents are selected from: tablet, pulvis, capsule, particle
Any one or more in agent, pill, suspension, syrup, mixture, powder and dripping pill.
9. application according to claim 1, which is characterized in that the icotinamide-adenine dinucleo or niacinamide-gland
Purine-oral single dose of phosphoric acid-dinucleotides is 0.1~10mg/kg, and taking orally number day is 1~3 time；
The icotinamide-adenine dinucleo or nicotinamide-adenine-phosphoric acid-dinucleotides injection single dose are 0.1
~2mg/kg.
10. application according to claim 1, which is characterized in that in the Claritin and/or antiallergy health care product,
Other antiallergic activities are not contained in addition to icotinamide-adenine dinucleo and/or nicotinamide-adenine-phosphoric acid-dinucleotides
Ingredient.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910503709.6A CN110200985A (en) | 2019-06-06 | 2019-06-06 | Application in NADH and/or NADPH Claritin and/or antiallergy health care product |
| PCT/CN2020/093955 WO2020244508A1 (en) | 2019-06-06 | 2020-06-02 | Application of nadh and/or nadph anti-allergic drugs and/or anti-allergic health food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910503709.6A CN110200985A (en) | 2019-06-06 | 2019-06-06 | Application in NADH and/or NADPH Claritin and/or antiallergy health care product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110200985A true CN110200985A (en) | 2019-09-06 |
Family
ID=67792094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910503709.6A Pending CN110200985A (en) | 2019-06-06 | 2019-06-06 | Application in NADH and/or NADPH Claritin and/or antiallergy health care product |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110200985A (en) |
| WO (1) | WO2020244508A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244508A1 (en) * | 2019-06-06 | 2020-12-10 | 泓博元生命科技（深圳）有限公司 | Application of nadh and/or nadph anti-allergic drugs and/or anti-allergic health food |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5188941A (en) * | 1988-02-12 | 1993-02-23 | Gds Technology, Inc. | Enzymatic determination of theophylline |
| US20020098277A1 (en) * | 1999-01-27 | 2002-07-25 | Buchanan Bob B. | Stabilization of hypoallergenic, hyperdigestible previously reduced proteins |
| US20060247200A1 (en) * | 2005-04-29 | 2006-11-02 | Cytometix, Inc. | Methods and uses of leukotriene B4 hydroxylases to treat diseases |
| CN109091663A (en) * | 2018-08-30 | 2018-12-28 | 泓博元生命科技（深圳）有限公司 | A kind of antianaphylactic composition and the preparation method and application thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7582606B2 (en) * | 2005-11-03 | 2009-09-01 | The Board Of Regents Of The University Of Texas System | Nadph oxidase cytosolic cofactor mutant |
| WO2017165665A1 (en) * | 2016-03-23 | 2017-09-28 | The General Hospital Corporation | Assays and methods for detecting udp-glucose |
| CN110200985A (en) * | 2019-06-06 | 2019-09-06 | 泓博元生命科技（深圳）有限公司 | Application in NADH and/or NADPH Claritin and/or antiallergy health care product |
-
2019
- 2019-06-06 CN CN201910503709.6A patent/CN110200985A/en active Pending
-
2020
- 2020-06-02 WO PCT/CN2020/093955 patent/WO2020244508A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5188941A (en) * | 1988-02-12 | 1993-02-23 | Gds Technology, Inc. | Enzymatic determination of theophylline |
| US20020098277A1 (en) * | 1999-01-27 | 2002-07-25 | Buchanan Bob B. | Stabilization of hypoallergenic, hyperdigestible previously reduced proteins |
| US20060247200A1 (en) * | 2005-04-29 | 2006-11-02 | Cytometix, Inc. | Methods and uses of leukotriene B4 hydroxylases to treat diseases |
| CN109091663A (en) * | 2018-08-30 | 2018-12-28 | 泓博元生命科技（深圳）有限公司 | A kind of antianaphylactic composition and the preparation method and application thereof |
Non-Patent Citations (1)
| Title |
|---|
| ISTVAN BOLDOGH等: "ROS generated by pollen NADPH oxidase provide a signal that augments antigeninduced allergic airway inflammation", 《THE JOURNAL OF CLINICAL INVESTIGATION》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020244508A1 (en) * | 2019-06-06 | 2020-12-10 | 泓博元生命科技（深圳）有限公司 | Application of nadh and/or nadph anti-allergic drugs and/or anti-allergic health food |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020244508A1 (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7012929B2 (en) | Egg protein preparation and its manufacturing method | |
| US9375444B2 (en) | Composition for prevention and treatment of allergic and/or inflammatory diseases | |
| JP2023502702A (en) | Novel use of Lactobacillus paracasei K56 in alleviating intestinal inflammation | |
| CN111265500B (en) | Pharmaceutical composition for preventing and treating COVID-19 and preparation method thereof | |
| Dantzer et al. | Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: a randomized, double-blind, placebo-controlled phase 2 trial | |
| CN110237088A (en) | A kind of application of nicotinamide mononucleotide and/or nicotinamide mononucleotide salt | |
| WO2020200212A1 (en) | Soil preparation for preventing and treating metabolic diseases and preparation method therefor and use thereof | |
| CN111575204B (en) | Lactobacillus paracasei capable of relieving or treating allergic diseases and application thereof | |
| WO2020051973A1 (en) | Application of terra flava usta in preparation of medicaments for preventing and treating allergic diseases, mental diseases, metabolic diseases, and endocrine disorders | |
| CN101291681A (en) | Cytokine modulators and related methods of use | |
| CN112999246A (en) | Probiotic composition, and product and application thereof | |
| CN110200985A (en) | Application in NADH and/or NADPH Claritin and/or antiallergy health care product | |
| WO2012071654A1 (en) | Treatment and prevention of eczema | |
| Furuta | Eosinophilic esophagitis: an emerging clinicopathologic entity | |
| CN108175849A (en) | Polaprezinc oral preparation and the application in ulcerative colitis drug is prepared | |
| CN112375722A (en) | Lactobacillus casei LC-12 for improving allergy, and product and application thereof | |
| CN116672370A (en) | Application of lactobacillus plantarum GUANKE immune strain in preparation of products for treating allergic rhinitis | |
| CN101829154B (en) | Preparation method of medicine composition for preventing and treating asthma | |
| Archer et al. | Milmed treatment alleviated or abolished allergy | |
| US20190167738A1 (en) | Compositions containing euglena gracilis for viral protection and related methods | |
| CN105194658A (en) | Traditional Chinese medicinal preparation for treating obesity and enhancing physique and preparation method of traditional Chinese medicinal preparation | |
| CN111281893B (en) | Application of mycobacterium vaccae for injection in preparation of medicament for preventing and treating COVID-19 | |
| CN117942355A (en) | Antiallergic pharmaceutical composition and medicine for preventing and/or treating diseases caused by allergic reaction | |
| Nadler | Effects of Natural Products on Inflammation | |
| CN116407569A (en) | Antiallergic probiotic composition and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190906 |
|
| RJ01 | Rejection of invention patent application after publication |